SGLT2抑制剂使用与2型糖尿病患者首次骨质疏松性椎体骨折后椎体强化风险的关联
本研究基于TriNetX全球协作网络的回顾性队列数据,纳入2型糖尿病合并骨质疏松且首次发生椎体压缩骨折的成人,比较骨折前6个月内使用SGLT2抑制剂者与未使用者的椎体强化风险。倾向评分匹配后每组各1757例,SGLT2抑制剂使用者6个月内椎体强化比例为12.5%,非使用者为9.3%,使用SGLT2抑制剂与椎体强化可能性升高相关(OR 1.40;95%CI 1.13-1.73;p=0.002)。
要点
- 匹配后SGLT2抑制剂组与非使用者组各1757例,基线特征均衡。
- 首次椎体骨折后6个月内椎体强化比例:SGLT2抑制剂组12.5% vs 非使用者组9.3%。
- SGLT2抑制剂使用与椎体强化可能性升高相关(OR 1.40;95%CI 1.13-1.73;p=0.002)。
核心结论
- 在2型糖尿病合并骨质疏松患者中,SGLT2抑制剂使用与首次骨质疏松性椎体骨折后椎体强化可能性升高相关,提示骨折后临床病程或管理强度可能存在差异。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络数据。
- 纳入2型糖尿病、骨质疏松且首次记录椎体压缩骨折的成人。
- 比较骨折前6个月内接受SGLT2抑制剂者与未使用者。
- 排除既往椎体强化、椎体恶性肿瘤或炎性脊柱病患者。
- 基于人口学、合并症和合并用药进行1:1倾向评分匹配,匹配后每组各1757例。
主要发现
- 匹配后每组各1757例,基线特征均衡良好。
- 首次椎体压缩骨折后6个月内,SGLT2抑制剂使用者中12.5%接受椎体强化,非使用者中为9.3%。
- SGLT2抑制剂使用与椎体强化可能性升高相关(OR 1.40;95%CI 1.13-1.73;p=0.002)。
关键数值与推荐
- 主要结局为指数骨折后6个月内椎体强化。
- SGLT2抑制剂暴露定义为骨折前6个月内使用。
- 匹配后SGLT2抑制剂组椎体强化12.5% vs 非使用者组9.3%(OR 1.40;95%CI 1.13-1.73;p=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in patients with type 2 diabetes mellitus (T2DM), but their influence on post-fracture outcomes remains unclear. This study aimed to evaluate the association between SGLT2 inhibitor use and the risk of vertebral augmentation after an initial osteoporotic vertebral compression fracture (VCF) in patients with T2DM and osteoporosis. METHODS: This retrospective cohort study used data from the TriNetX Global Collaborative Network. Adults with T2DM, osteoporosis, and a first documented VCF were identified. Patients who received SGLT2 inhibitors within 6 months prior to the fracture were compared with non-users. Individuals with prior vertebral augmentation, vertebral malignancy, or inflammatory spondylopathies were excluded. Propensity score matching (1:1) was performed based on demographics, comorbidities, and concurrent medications. The primary outcome was vertebral augmentation within 6 months following the index fracture. RESULTS: After matching, 1757 patients were included in each cohort with well-balanced baseline characteristics. Within 6 months after the initial VCF, vertebral augmentation was performed in 12.5% of SGLT2 inhibitor users and 9.3% of non-users. SGLT2 inhibitor use was associated with a higher likelihood of vertebral augmentation (odds ratio 1.40; 95% confidence interval 1.13-1.73; p = 0.002). CONCLUSION: In patients with T2DM and osteoporosis, SGLT2 inhibitor use was associated with an increased likelihood of vertebral augmentation following an initial osteoporotic vertebral fracture, suggesting potential differences in post-fracture clinical course or management intensity.
引用
- Chang Y, Chi KY, Chen CM, et al. Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes. Osteoporos Int. 2026. PMID: 41504956. doi:10.1007/s00198-025-07839-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。